Get the Stockscreener App
1.09
1.22%
-0.01
Opus Genetics Inc stock is traded at $1.09, with a volume of 59,338.
It is down -1.22% in the last 24 hours and up +9.53% over the past month.
Opus Genetics Inc is a clinical-stage ophthalmic biopharmaceutical company developing therapies to treat patients with inherited retinal diseases (IRDs) and therapies to treat patients with other retinal and refractive disorders. The pipeline includes adeno-associated virus (AAV)-based gene therapies that address mutations in genes that cause different forms of bestrophinopathy, Leber congenital amaurosis (LCA), and retinitis pigmentosa. The pipeline also includes Phentolamine Ophthalmic Solution 0.75%, a non-selective alpha-1 and alpha-2 adrenergic antagonist to reduce pupil size, and APX3330, a novel small-molecule inhibitor of Ref-1 to slow the progression of non-proliferative diabetic retinopathy.
See More
Previous Close:
$1.10
Open:
$1.1
24h Volume:
59,338
Relative Volume:
0.06
Market Cap:
$65.03M
Revenue:
$8.38M
Net Income/Loss:
$-27.19M
P/E Ratio:
-1.00
EPS:
-1.09
Net Cash Flow:
$-13.59M
1W Performance:
-2.11%
1M Performance:
+9.53%
6M Performance:
-5.51%
1Y Performance:
+0.00%
1-Day Range:
$1.0601
$1.11
1-Week Range:
$1.06
$1.1362
52-Week Range:
$0.65
$1.75
Opus Genetics Inc Stock (IRD) Company Profile
Name
Opus Genetics Inc
Sector
Industry
Phone
248-681-9815
Address
8 DAVIS DRIVE, DURHAM
Compare IRD with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
IRD
Opus Genetics Inc
|
1.09 | 66.22M | 8.38M | -27.19M | -13.59M | -1.09 |
|
VRTX
Vertex Pharmaceuticals Inc
|
384.64 | 96.11B | 11.42B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
560.36 | 60.40B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
430.31 | 54.91B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
670.26 | 41.30B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
295.12 | 33.25B | 3.81B | -644.79M | -669.77M | -6.24 |
Opus Genetics Inc Stock (IRD) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-11-25 | Initiated | Craig Hallum | Buy |
| Nov-13-24 | Resumed | H.C. Wainwright | Buy |
Opus Genetics Inc Stock (IRD) Latest News
Opus Genetics to Participate in the H.C. Wainwright 5th Annual Ophthalmology Virtual Conference - GlobeNewswire
Gene Therapy Leader Opus Genetics Showcases Retinal Disease Breakthroughs at Major Ophthalmology Conference - Stock Titan
What are the technical indicators suggesting about Opus Genetics Inc.Discover breakthrough investment opportunities - Jammu Links News
What is the dividend policy of Opus Genetics Inc. stockUnlock daily market insights for better trades - Jammu Links News
When is Opus Genetics Inc. stock expected to show significant growthBuild wealth faster with consistent growth stocks - Jammu Links News
What are Opus Genetics Inc. company’s key revenue driversFind market-beating stocks for your portfolio - Jammu Links News
How does Opus Genetics Inc. compare to its industry peersCapitalize on fast-moving market trends - Jammu Links News
What drives Opus Genetics Inc. stock priceInvest smarter with actionable market insights - Jammu Links News
What markets is PRTS expanding into Is Opus Genetics Inc. stock a good long term investment optionUnlock powerful trading signals and alerts - Jammu Links News
What is the risk reward ratio of investing in Opus Genetics Inc. stockFree Stock Market Real-Time Monitoring - Jammu Links News
How volatile is Opus Genetics Inc. stock compared to the marketAchieve consistent double-digit growth - Jammu Links News
Should I hold or sell Opus Genetics Inc. stock in 2025Game-changing returns - Jammu Links News
What is Opus Genetics Inc. company’s growth strategySuperior stock selection - Jammu Links News
What are analysts’ price targets for Opus Genetics Inc. in the next 12 monthsAchieve rapid financial growth with smart picks - Jammu Links News
Why is Opus Genetics Inc. stock attracting strong analyst attentionMaximize returns with disciplined trading approaches - Jammu Links News
Is a relief rally coming for Opus Genetics Inc. holdersTen-Year Sector Performance and Summary Analysis - Newser
Pro Bono Team Advises Global RDH12 Alliance and Eyes on the Future in Collaboration with Opus Genetics to Advance Gene Therapy for Inherited Childhood Blindness - Legal Desire Media and Insights
What high frequency data says about Opus Genetics Inc.Market Stability and Long-Term Growth Outlook - Newser
Institutional scanner results for Opus Genetics Inc.Trade Safety Matrix for Conservative Traders - Newser
Price momentum metrics for Opus Genetics Inc. explainedFree Low Risk Picks for Daily Trading - Newser
Can a trend reversal in Opus Genetics Inc. lead to recoveryFree Market Entry and Exit Point Tips - Newser
Will a bounce in Opus Genetics Inc. offer an exitSector Rotation Strategy for Smart Traders - Newser
Volatility clustering patterns for Opus Genetics Inc.Free Exit Ready Momentum Stock Watchlist - Newser
How Opus Genetics Inc. stock reacts to Fed policy changesOptimized Watchlist With Daily Adjustments Launched - beatles.ru
Opus Genetics and Global RDH12 Alliance announce partnership - Modern Retina
Why Opus Genetics Inc. stock attracts strong analyst attentionTriple Digit Return Stock Predictions Released - beatles.ru
Tick level data insight on Opus Genetics Inc. volatilityHistorical Volatility and Pattern Breakdown Analysis - Newser
What makes Opus Genetics Inc. stock price move sharplyMachine Learning Intraday Signal Forecast - Newser
Sentiment analysis tools applied to Opus Genetics Inc.Future Growth Stock Forecasting Strategy - Newser
Automated trading signals detected on Opus Genetics Inc.AI Short-Term Gain Forecast with Data - Newser
How Interest Rate Changes Impact Opus Genetics Inc. Stock PerformanceMarket Forecast Summary Over Multi-Year Period - Newser
Buy Signal for Opus Genetics Inc. Stock Key Technical Indicators to WatchBuy Point Strategy with Profit Protection - Newser
How Opus Genetics Inc. stock performs during market volatilitySmart Chart Forecasting with AI Algorithms - Newser
Does Opus Genetics Inc. stock perform well during market downturnsSuperior returns - Jammu Links News
Quantitative breakdown of Opus Genetics Inc. recent moveTechnical Trade Plan with Entry Checklist - Newser
Developing predictive dashboards with Opus Genetics Inc. data Free Proven Entry Plan With Low Risk Trade - Newser
Opus Genetics Inc Stock (IRD) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.36%
1.76%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):